Extracellular vesicles (EVs) play a key role in cell-to-cell communication. They are small vesicles that contain rich molecular cargo. Recently, they have been proposed as biomarkers for clinical diagnostics. EVs include three classes: small EVs (exosomes), large EVs (microparticles), and apoptotic bodies. Platelet-derived EVs (PEVs) are the most abundant class in human blood and can actively participate in numerous physiological and pathological processes. The information about the role of platelet exosomes in cardiovascular disease and the effect of antiplatelet agents on their release and content is very limited.
Eligibility
Sex
ALL
Min age
20 Years
Max age
60 Years
Healthy volunteers
Accepted
Inclusion Criteria:
* subjects without known pathologies
Exclusion Criteria:
* individuals with gastrointestinal diseases,
* individuals with history of hepatic diseases,
* individuals with history of urogenital diseases,
* individuals with history of hematological diseases,
* individuals with history of immunological diseases,
* individuals with history of renal diseases,
* individuals with history of metabolic diseases
* individuals with history of respiratory diseases
* individuals with history of cancer
* individuals with history of cardiovascular disease
* individuals having permanent organ damage
* individuals with major trauma in the last 6 months prior to enrollment
* individuals with surgery in the last 6 months prior to enrollment
* individuals taking medication in the 15 days prior to enrolment.
Primary outcome measure(s)
Characterization of exosomes released by activated platelet by Nanoparticle Tracking Analysis (NTA) and proteoma analysis — 36 month
Characterization of exosomes released by activated platelet and exposed to platelet inhibitors by NTA and proteoma analysis — 36 month
Trial sites (1)
Facility
City
Region
Status
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
